This is a cross-sectional, epidemiological study to determine the prevalence of cardiovascular risk factors such as obesity, smoking, dyslipidemia, diabetes mellitus and hypertension in patients attending General Practice clinics in the Africa and Middle East region. A total of 4300 patients will be evaluated. In patients who are found to have previously been diagnosed with cardiovascular (CV) risk factors such as dyslipidemia or hypertension, the level of control of their respective conditions will also be evaluated.
This is a cross-sectional, epidemiological study. In the course of this study, 4,300 persons from general practice, and other non specialist clinics of selected countries of the Africa and Middle East region, will be evaluated for the presence of cardiovascular (CV) risk factors such as obesity, smoking, dyslipidaemia, diabetes mellitus and hypertension. The degree of control of hypertension and dyslipidaemia in those previously diagnosed with these conditions will also be assessed. All medications used for CV risk factor control will also be ascertained. Patient evaluation will be done by physicians in charge of the selected clinics (who will be trained for case report forms completion) over one visit, through history taking, clinical examination as well as laboratory investigations. Every fifth patient seen on a particular day, fulfilling the inclusion and exclusion criteria would be included in the study.
Study Type
OBSERVATIONAL
Enrollment
4,386
Pfizer Investigational Site
Algiers, Algeria
Pfizer Investigational Site
Bejaja, Algeria
Pfizer Investigational Site
Djelfa, Algeria
Pfizer Investigational Site
Laghouat, Algeria
Pfizer Investigational Site
M'Sila, Algeria
Pfizer Investigational Site
Prevalence of cardiovascular (CV) risk factors such as obesity, smoking, dyslipidemia, diabetes mellitus and hypertension
Time frame: At the time of the first visit
Compare the prevalence of cardiovascular (CV) risk factors such as obesity, smoking, dyslipidaemia, diabetes mellitus and hypertension in the urban and rural population.
Time frame: At the time of the first visit
Compare the prevalence of CV risk factors such as obesity, smoking, dyslipidaemia, diabetes mellitus and hypertension in the male and female population.
Time frame: At the time of the first visit
Stratifying the prevalence of CV risk factors such as obesity, smoking, dyslipidaemia, diabetes mellitus and hypertension by age groups.
Time frame: At the time of the first visit
Ascertain the level of blood pressure and lipids' control as per the European Society of Cardiology (ESC) guidelines in patients who have been previously diagnosed as hypertensive or dyslipidaemic.
Time frame: At the time of the first visit
Ascertain the most commonly used medications in those that have been previously diagnosed as diabetic, hypertensive or dyslipidaemic.
Time frame: At the time of the first visit
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Relizane, Algeria
Pfizer Investigational Site
Saida, Algeria
Pfizer Investigational Site
Tébessa, Algeria
Pfizer Investigational Site
Tlemcen, Algeria
Pfizer Investigational Site
Yaoundé, Cite Verte, Cameroon
...and 63 more locations